A PHASE II TRIAL OF TAMOXIFEN AND BORTEZOMIB IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA

被引：0
|
作者：
Aregawi, Dawit [1 ]
Kreisl, Teri N. [2 ]
Innis, Ellen [3 ]
Fine, Howard A. [4 ]
机构：
[1] NCI, Neurooncol Branch, Bethesda, MD 20892 USA
[2] Columbia Univ, Neurol Inst, New York, NY USA
[3] Univ Maryland, Baltimore, MD 21201 USA
[4] NYU, Inst Canc, NYU Langone Med Ctr, New York, NY USA
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
10.1093/neuonc/nou237.6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AT-06
引用
收藏
页数：1
相关论文
共 50 条
  • [21] VORINOSTAT AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMA: INTERIM ANALYSIS OF A PHASE II CLINICAL TRIAL
    Peters, Katherine
    Reardon, David
    Randazzo, Dina
    Dutton, Shelley
    Edwards, Ashley
    Lipp, Eric
    Herndon, James, II
    McSherry, Frances
    Desjardins, Annick
    Ranjan, Tulika
    Vlahovic, Gordana
    Friedman, Henry
    NEURO-ONCOLOGY, 2014, 16
  • [22] Phase II study of sunitinib and irinotecan in patients with recurrent high-grade glioma (HGG).
    Grisanti, S.
    Pedersini, R.
    Ferrari, V. D.
    Liserre, R.
    Consoli, F.
    Poliani, L.
    Boglione, M.
    Rangoni, G.
    Montini, E.
    Simoncini, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
    Kreisl, Teri N.
    Kotliarova, Svetlana
    Butman, John A.
    Albert, Paul S.
    Kim, Lyndon
    Musib, Luna
    Thornton, Donald
    Fine, Howard A.
    NEURO-ONCOLOGY, 2010, 12 (02) : 181 - 189
  • [24] Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas
    Fine, HA
    Wen, PY
    Maher, EA
    Viscosi, E
    Batchelor, T
    Lakhani, N
    Figg, WD
    Purow, BW
    Borkowf, CB
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2299 - 2304
  • [25] A phase II study of anlotinib in the treatment of recurrent high-grade glioma
    Dai, H.
    Zhang, M.
    Zhang, Q.
    Zhao, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S521 - S522
  • [26] VORINOSTAT, BEVACIZUMAB, AND METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE GLIOMA: A PHASE I/II CLINICAL TRIAL
    Peters, Katherine B.
    Reardon, David A.
    Vredenburgh, James J.
    Desjardins, Annick
    Herndon, James E., II
    Coan, April
    McSherry, Frances
    Lipp, Eric
    Brickhouse, Alise
    Massey, Woody
    Friedman, Henry S.
    NEURO-ONCOLOGY, 2012, 14 : 81 - 81
  • [27] Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma
    Han, Seunggu J.
    Rolston, John D.
    Molinaro, Annette M.
    Clarke, Jennifer L.
    Prados, Michael D.
    Chang, Susan M.
    Berger, Mitchel S.
    DeSilva, Ashley
    Butowski, Nicholas A.
    NEURO-ONCOLOGY, 2014, 16 (09) : 1255 - 1262
  • [28] Phase I trial of bortezomib in adults with recurrent malignant glioma.
    Phuphanich, S.
    Supko, J.
    Carson, K. A.
    Grossman, S. A.
    Nabors, L. B.
    Mikkelsen, T.
    Lesser, G.
    Rosenfeld, M.
    Desideri, S.
    Olson, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 74S - 74S
  • [29] Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma
    Phuphanich, Surasak
    Supko, Jeffrey G.
    Carson, Kathryn A.
    Grossman, Stuart A.
    Nabors, L. Burt
    Mikkelsen, Tom
    Lesser, Glenn
    Rosenfeld, Steve
    Desideri, Serena
    Olson, Jeffrey J.
    JOURNAL OF NEURO-ONCOLOGY, 2010, 100 (01) : 95 - 103
  • [30] Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma
    Surasak Phuphanich
    Jeffrey G. Supko
    Kathryn A. Carson
    Stuart A. Grossman
    L. Burt Nabors
    Tom Mikkelsen
    Glenn Lesser
    Steve Rosenfeld
    Serena Desideri
    Jeffrey J. Olson
    Journal of Neuro-Oncology, 2010, 100 : 95 - 103
12345